5 Results for "

bone metastatic growth

" in MedChemExpress (MCE) Product Catalog:
Products (5)

5 Results for "bone metastatic growth" in MCE Product Catalog:

Dabogratinib
Dabogratinib
0 Images
Cat. No.: HY-159642
CAS No.: 2800223-30-5
Synonyms: TYRA-300
Target:  

FGFR ERK

Research Areas:  

Metabolic Disease Cancer

Dabogratinib (TYRA-300) is an orally active, selective FGFR3 inhibitor with an IC50 of 11 nM. Dabogratinib exhibits antitumor activity against urothelial carcinoma and solid tumors. Dabogratinib downregulates the FGFR3 and ERK1/2 signaling pathways, and induces tumor growth inhibition and regression in FGFR3-altered xenograft models. Dabogratinib promotes chondrocyte proliferation and differentiation, drives endochondral bone formation and overall body growth, partially restores long bone proportions, and improves craniofacial and spinal morphology. Dabogratinib can be used for the research of metastatic urothelial carcinoma, achondroplasia and hypochondroplasia .
loading...
    loading...
View All Sizes
Pelgifatamab
Pelgifatamab
0 Images
Cat. No.: HY-P9992
CAS No.: 2414550-93-7
Synonyms: BAY-2315497; PSMA-TTC

Target:  

PSMA Apoptosis

Research Areas:  

Cancer

Peligifatamab is a PSMA-targeted α-radioimmunoconjugate with an EC50 of 1.2 nM against human targets. Peligifatamab induces DNA damage, DNA double-strand breaks, cell cycle arrest and apoptosis (Apoptosis) in PSMA-positive prostate cancer cells. Peligifatamab reduces cell viability in a manner dependent on cellular PSMA expression levels. Peligifatamab inhibits tumor growth and tumor-induced abnormal bone growth in prostate cancer bone metastasis models. Peligifatamab exhibits antitumor efficacy in subcutaneous prostate cancer models and xenograft models. Peligifatamab can be used for the research of metastatic castration-resistant prostate cancer .
loading...
    loading...
View All Sizes
huATN-658
huATN-658
0 Images
Cat. No.: HY-P990552A

Target:  

PAI-1 Integrin

Research Areas:  

Cancer

huATN-658 is an inhibitor that specifically targets the DIII domain of human urokinase plasminogen activator receptor (uPAR). huATN-658 neutralizes uPAR function by blocking the interaction between uPAR and integrins, without interfering with the binding of uPA or vitronectin to uPAR. huATN-658 inhibits the proliferation and invasion of breast cancer cells, slows the growth of primary breast tumors, reduces breast cancer-induced bone lesions and decreases osteoclast activity. huATN-658 also alters the gene expression of the TGF-β receptor complex signaling pathway. huATN-658 exerts synergistic anticancer effects when combined with Zoledronic Acid (HY-13777), and does not cause physiological or behavioral abnormalities in immunodeficient mice. huATN-658 can be used in research related to breast cancer, metastatic breast cancer and breast cancer-induced bone disease .
loading...
    loading...
View All Sizes
Dabogratinib (GMP)
Dabogratinib (GMP)
0 Images
Cat. No.: HY-159642G
CAS No.: 2800223-30-5
Synonyms: TYRA-300 (GMP)
Dabogratinib (TYRA-300) (GMP) is Dabogratinib (HY-159642) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. Dabogratinib is an orally active, selective FGFR3 inhibitor with an IC50 of 11 nM. Dabogratinib exhibits antitumor activity against urothelial carcinoma and solid tumors. Dabogratinib downregulates the FGFR3 and ERK1/2 signaling pathways, and induces tumor growth inhibition and regression in FGFR3-altered xenograft models. Dabogratinib promotes chondrocyte proliferation and differentiation, drives endochondral bone formation and overall body growth, partially restores long bone proportions, and improves craniofacial and spinal morphology. Dabogratinib can be used for the research of metastatic urothelial carcinoma, achondroplasia and hypochondroplasia .
loading...
    loading...
View All Sizes
BKM1644
BKM1644
0 Images
Cat. No.: HY-119001
CAS No.: 1070966-96-9
Target:  

Survivin

Research Areas:  

Cancer

BKM1644, an acyl-tyrosine bisphosphonate amide derivative, exhibits potent anti-cancer activity. BKM1644 effectively inhibits the proliferation of metastatic, castration-resistant prostate cance (mCRPC) cells. BKM1644 sensitizes mCRPC cells to Docetaxel (HY-B0011) and retards the bone metastatic growth of prostate cance .
loading...
    loading...
View All Sizes
Assay Types